Regenxbio (RGNX) Accounts Payables (2014 - 2026)

Regenxbio's Accounts Payables history runs 12 years deep, the most recent figure standing at $21.4 million for Q4 2025.

• In Q4 2025, Accounts Payables fell 6.32% year-over-year to $21.4 million; the TTM figure through Dec 2025 stood at $21.4 million (down 6.32% YoY), while the FY2025 annual figure was $21.4 million, down 6.32% from the prior year.
• Accounts Payables for Q4 2025 stood at $21.4 million, down from $22.3 million in the prior quarter.
• The five-year high for Accounts Payables was $31.4 million in Q1 2024, with the low at $9.4 million in Q2 2021.
• The 5-year median for Accounts Payables is $21.5 million (2025), against an average of $20.0 million.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 138.98% in 2022, then sank 39.27% in 2025.
• Regenxbio's Accounts Payables stood at $11.4 million in 2021, then soared by 138.98% to $27.2 million in 2022, then decreased by 16.27% to $22.8 million in 2023, then increased by 0.05% to $22.8 million in 2024, then dropped by 6.32% to $21.4 million in 2025.
• Business Quant data shows RGNX's Accounts Payables at $21.4 million in Q4 2025, $22.3 million in Q3 2025, and $21.7 million in Q2 2025.